ENDV (Endonovo Therapeutics) Tariff Resilience Score: 4/10 (As of Jun. 27, 2026)


What is Endonovo Therapeutics Tariff Resilience Score?

Endonovo Therapeutics ENDV -99.00% Tariff Resilience Score is 4 as of Jun. 27, 2026. The stock has 3 warning signs investors should review. Among 1,378 Biotechnology companies, Endonovo Therapeutics ranks better than 52.39% on this metric.

Endonovo Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Endonovo Therapeutics has Endonovo relies on global suppliers for medical device components, making it vulnerable to tariffs. Limited manufacturing flexibility and a focus on the US market increase exposure. Historical tariffs have impacted costs, but some mitigation through alternative suppliers is possible.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Endonovo Therapeutics might have Average Resilient.

Endonovo Therapeutics  (OTCPK:ENDV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Endonovo Therapeutics Tariff Resilience Score Related Terms

ENDV vs RGBP, IOBTQ, CNBX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 4 mean?
Endonovo Therapeutics (ENDV) has a Tariff Resilience Score of 4 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Endonovo Therapeutics ranks #656 out of 1378 companies in the Biotechnology industry, placing it in the top 47.6%.
Is Endonovo Therapeutics' Tariff Resilience Score too high?
Endonovo Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Endonovo Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Endonovo Therapeutics ranks #656 out of 1378 companies in the Biotechnology industry, which is above the industry midpoint.
How does Endonovo Therapeutics' Tariff Resilience Score compare to RGBP and IOBTQ?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #656 out of 1378 companies for Tariff Resilience Score. This puts Endonovo Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Endonovo Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Endonovo Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Tariff Resilience Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.